Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
G1 Therapeutics, Inc. (GTHX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
06/16/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
06/09/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH"
05/03/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/01/2023 8-K Quarterly results
02/13/2023 8-K Quarterly results
01/09/2023 8-K Investor presentation
Docs: "41st Annual J.P. Morgan Healthcare Conference Wednesday January 11, 1:30 PM PT Advancing"
11/18/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
08/03/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "G1 Therapeutics Provides Second Quarter 2022 Financial Results and Operational Highlights - Achieved $8.7 Million in Net Revenue from Sales of COSELA® in the Second Quarter of 2022 and $10.6 Million in Total Revenue -"
07/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors"
06/28/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
02/23/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights - Achieved $5.8 Million in Total Revenue in the Fourth Quarter of 2021, Including $4.4 Million in Net Revenue from Sales of COSELA ™ - - Completed Hiring, Training, and Deployment of G1's COSELA Sales Team - - Announced That Initial Results from Phase 3 Trial of Trilaciclib in Colorectal Cancer Are Now Expected Early in the First Quarter of 2023 - - Initiated Two New Phase 2 Trials to Confirm the Immune-Based Mechanism of Action of Trilaciclib and to Help Clarify the Potential Synergistic Effects of Trilaciclib and an Antibody-Drug Conjugate - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, NC, February 23, 2022 - G1 Therapeutics, Inc. , a c..."
01/10/2022 8-K Investor presentation
Docs: "Presentation dated January 2022",
"Presentation dated January 2022"
12/16/2021 8-K Quarterly results
11/03/2021 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obl...
Docs: "G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights - Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA ™ - - Announced Supplemental COSELA Sales Force to Target Top Tier Accounts and Publication of Permanent J-Code for COSELA— - Initiation of Two New Phase 2 Trials Expected in the Fourth Quarter of 2021 to Further Investigate Trilaciclib's Immune-Based Mechanism of Action and Potential Benefits in Combination with an Antibody-Drug Conjugate - - Amended Debt Facility Extends Cash Runway into 2024 - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, NC, November 3, 2021 - G1 Therapeutics, Inc. , a commercial-stage oncology company, today provided a corporate and ..."
10/15/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/15/2021 8-K Quarterly results
08/04/2021 8-K Quarterly results
08/02/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer"
07/02/2021 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi...
Docs: "Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., (incorporated by reference as Exhibit 5.1 to the Company’s Registration Statement on Form S-3ASR filed with the SEC on July 2, 2021)",
"Certificate of Correction to G1 Therapeutics, Inc.’s Amended and Restated Certificate of Incorporation filed on May 22, 2017"
06/21/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
04/23/2021 8-K Quarterly results
03/30/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/04/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "G1 Therapeutics Provides Third Quarter 2020 Corporate and Financial Update"
09/30/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy